Why Multi-Pathway Metabolic Research Is Accelerating

Metabolism is not controlled by one switch, so it's perhaps unsurprising that metabolic research moved from single-target compounds toward molecules that engage several receptors at once. The incretin field is the clearest example — and the reason “multi-pathway” has become a defining theme. What follows is a research summary, for laboratory use only.

From single target to dual agonist

GLP-1 receptor agonists established the template. The next step combined GLP-1 with a second incretin receptor, GIP — the dual-agonist approach studied with tirzepatide, summarized in mechanistic reviews of the combined pharmacology (Nauck & D'Alessio, Cardiovasc Diabetol, 2022). [1]

Adding a third pathway

Triple agonists go further by adding glucagon-receptor activity — associated with energy expenditure — to GLP-1 and GIP. Retatrutide is the research archetype, introduced as a novel GLP-1/GIP/glucagon agonist (Coskun et al., Cell Metab, 2022). [2] The logic is that hitting complementary nodes may do more than maximizing one.

The combination frontier

The same multi-pathway thinking shows up in research pairing metabolic agonists with mitochondrial-support compounds — a recognition that signalling and cellular energy are different levers on the same system.